Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 22,600 shares, a decline of 60.8% from the December 31st total of 57,600 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average daily volume of 175,600 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Several equities analysts have weighed in on ADIL shares. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Adial Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $8.00 price target on the stock.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock opened at $0.86 on Thursday. Adial Pharmaceuticals has a 12-month low of $0.72 and a 12-month high of $4.17. The firm has a fifty day moving average of $1.04 and a 200-day moving average of $1.03.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.